Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR. Wang B, Wang Y, Zhu Y, Guo L, et al. Br J Cancer 2025;133:255-269.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang B, Wang Y, Zhu Y, Guo L, et al. Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR. Br J Cancer 2025;133:255-269.
PMID: 40341250